Marks Group Wealth Management Inc Raises Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Marks Group Wealth Management Inc lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 8.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,009 shares of the company's stock after purchasing an additional 869 shares during the quarter. Marks Group Wealth Management Inc's holdings in IDEXX Laboratories were worth $4,552,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. FSA Wealth Management LLC acquired a new stake in IDEXX Laboratories in the third quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. grew its stake in IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock valued at $29,000 after acquiring an additional 57 shares during the period. Retirement Wealth Solutions LLC acquired a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $31,000. Mowery & Schoenfeld Wealth Management LLC grew its stake in IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company's stock valued at $34,000 after acquiring an additional 60 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new stake in IDEXX Laboratories in the third quarter valued at approximately $37,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the business's stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. The trade was a 27.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the business's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 13,330 shares of company stock worth $6,161,276 over the last ninety days. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Stock Performance

Shares of IDXX traded down $15.23 during mid-day trading on Friday, hitting $444.53. The stock had a trading volume of 553,751 shares, compared to its average volume of 753,210. The firm has a market cap of $36.40 billion, a P/E ratio of 41.66, a PEG ratio of 3.47 and a beta of 1.37. The business has a fifty day moving average price of $430.95 and a 200-day moving average price of $453.11. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 1.03. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several analyst reports. Morgan Stanley cut their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Bank of America lifted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Wednesday, February 5th. Barclays lifted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Finally, Leerink Partners assumed coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price objective on the stock. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.